Renal Anemia

1. Front Matter

   Pages i-xi

   PDF

2. Correcting anemia slows renal disease progression

   • Eli A. Friedman

   Pages 1-7

3. Does treatment with EPO improve RBC survival?

   • Clinton D. Brown, Zhong H. Zhao, Lorraine L. Thomas, Robert deGroof, Eli A. Friedman

   Pages 9-13

4. Has the best route of administration for epoetin been established?

   • Anatole Besarab, Rebecca Schmidt

   Pages 15-28

5. Is renal anemia management determined by science or reimbursement regulations?

   • Chaim Charytan

   Pages 29-35

6. When does anemia impact the heart in chronic kidney disease?

   • Adeera Levin

   Pages 37-47

7. Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein

   • Jill S. Lindberg

   Pages 49-64

8. Normalizing hematocrit in renal failure: dangerous or desirable?

   • Iain C. Macdougall

   Pages 65-80

9. Do race, gender or mode of dialysis modulate erythropoietin response?

   • Barbara G. Delano

   Pages 81-88

10. Are uremic inhibitors of erythropoiesis clinically relevant?

    • Onyekachi Ifudu

    Pages 89-98

11. Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever?

    • Moro O. Salifu

    Pages 99-106

12. Is secondary hyperparathyroidism a significant cause of renal anemia?

    • Onyekachi Ifudu

    Pages 107-113

13. Is long-term intravenous iron therapy risky?

    • Wendy L. St. Peter

    Pages 115-121

14. Anemia and erythropoietin therapy in kidney transplant recipients: where are the data?

    • Onyekachi Ifudu

    Pages 123-128

15. Intravenous iron treatment: a comparison of available drugs

    • Steven Fishbane

    Pages 129-138

16. Epilogue

    • Eli A. Friedman

    Pages 139-140

17. Back Matter

    Pages 141-145

    PDF

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

• anemia
• erythropoietin
• kidney
• nephrology
• sepsis
• diabetes

• Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, USA

  Onyekachi Ifudu

Policies and ethics